4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients

Background

Inflammation impacts each step of tumorigenesis, including tumor initiation, promotion and metastatic progression. Biomarkers including the neutrophil, lymphocyte and platelet count, as well as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) are indices of inflammation. The aim of the present study was to assess the blood the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) as a prognostic factors in male breast cancer patients (BC).

Methods

A the retrospective analysis of 38 male BC patients who were treated at COI (Gliwice, Poland) between January 2005 and December 2018 was performed. Based on the cut-off values determined, the NLR was considered as ‘elevated’ at > 2.65, the MLR value was ‘elevated’ at > 0.28 and the PLR was considered ‘elevated’ at > 190.9. The prognostic value (OS) of the pre-treatment PLR, NLR and MLR was assessed by univariate analysis.

Results

There was observed tendency to worse 5-year OS in male BC patients with lymph node metastases (N+) (43.5% vs. 73.9%, p = 0.171); higher tumor size (T4 vs. T1) (42% vs.85.79%, p = 0.128); negative steroid receptor status (PR-) (28.6% vs. 65.6%, p = 0.109). Patients with cancer family history had significantly better 5-year OS than patients without cancer family history (86.3% vs.35.0%, p = 0.004).Younger male BC patients (age ≤53 years) had better 5 year OS in comparison to patients over 53 years (88.9% vs. 43.1%, p = 0.014).The 5-year OS was lower in patients with lower lymphocyte value ≤1.52 (24.0% vs. 67.4%, p = 0.010). There was reported tendency to the worse 5-year OS in patients with higher PLT value (PLT>193 x 10^3) (47.3% vs. 78.8%, p = 0.157). The 5-year OS was lower in the NLR >2.75 compared with that in the NLR≤2.75 group (29.6% vs. 64.4%, p = 0.031). Similarly, a worse OS rate was associated with an elevated PLR (>114.5) (34.4% vs.77.5%, p = 0.021). There was detected tendency to worse OS in group with lower MLR level (≤3.23) (39.5% vs. 71.9%, p = 0.155).

Conclusions

The present results revealed that an elevated NLR (>2.75) and PLR (>114.5) are associated with poor OS in male breast cancer patients. In contrary, the elevated MLR affected better OS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.